Taurine
Taurine is a sulfonic acid produced by the body itself; human studies show benefits for blood pressure, vascular function and blood sugar, but the data on endurance performance are uncertain.
We evaluated 153 human studies on Taurine, including 51 randomised controlled trials and 21 meta-analyses or systematic reviews; the controlled studies include 1,885 participants in total. As of 8 October 2026.
1. What Is Taurine? Occurrence, Origin and Forms
Taurine is a sulfur-containing compound that chemically belongs to the sulfonic acids and, unlike the proteinogenic amino acids, is not incorporated into proteins. The body produces it from cysteine and methionine itself and takes most of it in through animal foods. Taurine is known as an additive in energy drinks and infant formula, and as a dietary supplement it is offered in powder or capsule form.
Taurine occurs in animal tissues, especially abundantly in fish and seafood, and also in meat and milk. In the human body it is found in many tissues, among others in cardiac and skeletal muscle, in the retina and in the brain, and it is present in breast milk.
For dietary supplements, taurine is produced industrially, mostly by chemical synthesis. Studies examine above all oral forms as a single substance, alongside taurine-containing drinks, eye drops, and taurine in parenteral nutrition solutions and in infant formula.
Forms and Preparations Studied
- Taurine as a single substance, taken as powder or capsules
- Taurine-containing soft drinks, usually together with caffeine, sugar and other additives (mixture)
- Taurine eye drops for application to the eye
- Taurine in parenteral nutrition solutions (infusion)
- Taurine in infant formula
- Taurine in dietary supplements with other substances (combination product)
Not covered on this page:
- Energy drinks as a beverage category, whose effect cannot be attributed to taurine alone
- Caffeine and other individual ingredients of energy drinks
- Homotaurine, known as the drug acamprosate, a different molecule
- Bile acid conjugates such as taurocholic acid, in which taurine is bound
2. What Does Taurine Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Physical performance | mixed | high | 5 meta-analyses · 17 controlled · 10 other | 277 |
| Heart and circulation | mostly improved | high | 3 meta-analyses · 12 controlled · 9 other | 296 |
| Blood sugar and metabolism | mostly improved | high | 5 meta-analyses · 5 controlled · 9 other | 251 |
| Blood pressure | mostly improved | moderate | 7 meta-analyses · 1 controlled · 3 other | 0 |
| Nerves and brain | mostly no difference | low | 4 meta-analyses · 5 controlled · 21 other | 128 |
| Aging and longevity | mostly improved | low | 0 meta-analyses · 1 controlled · 5 other | 24 |
| Eye and retina | reviews only | low | 1 meta-analyses · 0 controlled · 5 other | 0 |
| Other investigations | mostly improved | high | 9 meta-analyses · 38 controlled · 41 other | 1,484 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Taurine and Physical Performance: Human Studies
A meta-analysis found small performance benefits after a single taurine dose, especially for endurance and strength, with low certainty of evidence 5. In two randomized controlled trials in humid heat, young adults with taurine lasted longer, but only at certain doses 5657. Another meta-analysis found better jumping performance than with placebo 16, and a randomized controlled trial found more anaerobic performance in speed skaters 43. After eccentric strength training, strength recovered better in two randomized controlled trials than with placebo 5164. A meta-analysis found less lactate dehydrogenase after exertion, and a benefit for muscle pain only at a late time point 10; a randomized controlled trial also showed less muscle soreness 51. A small controlled trial in runners found lower AST and inflammation values, but no difference in creatine kinase 76. These are contrasted by results with no difference: a meta-analysis found no benefit in maximal oxygen uptake 16, and two controlled trials found none in time to exhaustion 5574. The findings come predominantly from small, short studies in young, trained men; the intake duration ranged from an acute single dose to several weeks. In two randomized controlled trials, the combination of taurine and caffeine improved individual performance values, while taurine alone did not 4154. In a third study, the combination brought no benefit in repeated sprints 58. It remains open whether the effects persist in women, older people and over longer periods.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2026 | systematic review · 1,030 participants | Taurine supplementation; optimal 3,000 mg daily; vs. Control in included trials | exercise capacity: improved |
| 5 Deng et al. 2025 | meta-analysis · 308 participants | Acute single taurine dose, capsule or beverage formulation; commonly used 1-6 g range; single ingestion, about 1 h before exercise; vs. control/placebo in randomized trials | overall performance: improved (g = 0.25, 95% CI [0.10, 0.39]); aerobic endurance, strength/power, agility/coordination: improved; anaerobic capacity and muscular endurance: unclear |
| 10 Dehghani et al. 2025 | meta-analysis · 165 participants | Taurine supplementation (form/dose not reported); vs. Placebo or control group | Creatine kinase post-exercise: improved (WMD = −7.91 IU/L, 95 % CI: −122.21 to 138.04); Creatine kinase after 24 h: improved (WMD = −78.28 IU/L, 95 % CI: −211.55 to 54.99); Lactate dehydrogenase post-exercise to 48 h: improved |
| 16 Buzdağlı et al. 2022 | meta-analysis | Taurine supplement; vs. Placebo group | Vertical jump performance: improved (MD =3.60; 95% CI 2.32 to 4.89, p <0.00001); Countermovement jump performance: improved (MD = 8.50; 95% CI 4.78 to 12.22, p <0.00001); VO2max: no difference (MD = −0.54 ml/kg/min; 95% CI −6.84 to 5.75, p=0.87) |
| 21 Kurtz et al. 2021 | systematic review | Taurine as sole ingredient, oral intake; <1 g to 6 g, acute or chronic; acute 10-15 min to 2 h before exercise; chronic 7 days to 8 weeks; vs. no uniform control, 19 included studies | VO2max: improved; time to exhaustion (TTE), n = 5 articles: improved (n = 5 articles); 3 or 4 km time-trial, n = 2 articles: improved (n = 2 articles) |
| 41 Köse et al. 2026 | randomised controlled · 32 participants | Taurine 10 mg/kg oral, alone and with caffeine 2 mg/kg; Taurine 10 mg/kg; caffeine 2 mg/kg; acute single dose; vs. placebo and caffeine alone, double-blind randomized crossover | handgrip strength: no difference (p = 0.044; d = 0.51); average power: no difference (p = 0.001; d = 0.91); peak power: no difference (p > 0.05) |
| 43 Buzdağlı et al. 2023 | randomised controlled · 30 participants | oral taurine; single 6 g dose; 60 minutes before testing, 72-hour washout; vs. placebo 6 g | peak power output in Wingate test: improved (Δ% = 13.41, p < 0.001, d = 1.71); mean power output in Wingate test: improved (Δ% = 3.95, p = 0.002, d = 1.04); minimum power output in Wingate test: improved (Δ% = 7.89, p = 0.034, d = 0.48) |
| 48 De et al. 2021 | randomised controlled · 24 participants | Taurine supplementation or placebo; 3 g taurine; 8 weeks; vs. Tau alone, Ex alone, TauEx, placebo | Resting energy expenditure: no difference |
Further studies in this area: 51 52 54 55 56 57 58 60 63 64 74 76 77 78 81 97 118 120 122 123 124 129 143 144
Taurine, Heart and Circulation: Human Studies
In three randomized controlled trials, vascular function or arterial stiffness improved more than with placebo, including in people with diabetes 466566. One meta-analysis found a lower heart rate and, in heart failure, a higher ejection fraction and a better NYHA class 3. A systematic review, by contrast, found no confirmed difference in ejection fraction and stroke volume in heart failure 18. The findings come predominantly from small, short studies; the optimal dose and long-term effect remain open. A controlled trial with a mixture of caffeine and taurine found no difference in skin blood flow 75.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Tzang et al. 2024 | meta-analysis · 808 participants | Taurine (form not specified); not reported, meta-regression by total dose; not reported; vs. control group | heart rate: improved (WMD = -3.579 bpm, 95% CI = -6.044 to -1.114, p = 0.004); left ventricular ejection fraction: improved (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004); NYHA functional classification: improved (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001) |
| 13 Nie et al. 2026 | meta-analysis | Oral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trials | Triglycerides: improved (MD, -14.42 mg/dL; 95% CI, -23.60 to -5.25); Total cholesterol: improved (MD, -12.41 mg/dL; 95% CI, -19.10 to -5.71); LDL cholesterol: improved (MD, -5.08 mg/dL; 95% CI, -8.35 to -1.81) |
| 18 McGurk et al. 2022 | systematic review | Taurine supplementation; formulations: tablet, capsule, drink, powder; 500 mg to 6 g per day; 2 to 48 weeks; vs. no uniform comparator; studies heterogeneous | ejection fraction in all-cause heart failure: no difference (P<0.05); stroke volume in all-cause heart failure: no difference; diastolic and systolic function, exercise capacity, haemodynamic parameters: unclear |
| 25 Moludi et al. 2022 | randomised controlled · 120 participants | Taurine 1 g versus placebo, plus low-calorie diet; 1 g taurine three times per day; eight weeks; vs. placebo plus low-calorie diet | endothelial markers ICAM-1, VCAM, MMP-9: improved |
| 36 Samadpour et al. 2021 | randomised controlled · 40 participants | oral taurine supplementation; 8 weeks; vs. TRX+placebo, taurine alone, control | HDL cholesterol: improved; total cholesterol: improved; LDL cholesterol: no difference |
| 45 Ra et al. 2019 | randomised controlled · 29 participants | taurine supplement vs. placebo; 6 g/day; 2 weeks before and 3 days after exercise; vs. placebo group | Relative and absolute flow-mediated dilation at rest: improved (significantly increased both relative and absolute FMDs); FMD reduction 96 h after resistance exercise: no difference (does not affect resistance exercise-induced reduction in FMD) |
| 46 Ra et al. 2016 | randomised controlled · 29 participants | oral taurine, placebo; 2.0 g taurine or placebo, 3 times per day; 14 days before, on day of, and 3 days after exercise; vs. placebo-controlled, double-blind, randomized | carotid-femoral pulse wave velocity (cfPWV): improved (significantly attenuated) |
| 54 Karayigit et al. 2021 | randomised controlled · 17 participants | Taurine alone, caffeine alone, caffeine+taurine, placebo; 1 g taurine; 6 mg/kg caffeine; ingested 60 min before 30-s Wingate test; vs. placebo and caffeine alone or taurine alone | heart rate: no difference (p > 0.05) |
Further studies in this area: 56 60 65 66 70 74 77 79 97 115 119 120 139 142 145 146
Taurine, Blood Sugar and Metabolism: Human Studies
Several meta-analyses found lower fasting blood sugar with oral taurine, and in people with diabetes also lower long-term blood sugar and less insulin resistance 12813. In two randomized controlled trials in type 2 diabetes, fasting blood sugar, insulin and insulin resistance decreased more than with placebo 3132. A third study found a benefit only for insulin and insulin resistance, not for blood sugar 25. For blood lipids, two meta-analyses found lower triglycerides 222 and a randomized controlled trial found lower total and LDL cholesterol 31. A meta-analysis in diabetes and another randomized controlled trial found no difference in blood lipids 825. For inflammatory markers, oxidative stress and CAT activity, a randomized controlled trial found improvements, while it remained without difference for IL-6 and TAC 29. Taurine had no independent influence on resting metabolic rate in two randomized controlled trials with training in obese women 4849.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2026 | systematic review · 1,030 participants | Taurine supplementation; optimal 3,000 mg daily; vs. Control in included trials | HbA1c, fasting glucose, fasting insulin, HOMA-IR: improved |
| 2 Tzang et al. 2024 | meta-analysis · 1,024 participants | Taurine supplementation (powder/capsule); 0.5 to 6 g per day; 5 to 365 days; vs. Control group | Fasting blood glucose: improved (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018); Triglycerides: improved (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001); HDL cholesterol: no difference (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155) |
| 8 Tao et al. 2022 | meta-analysis · 209 participants | Taurine supplement; vs. Control group | HbA1c: improved (SMD -0.41[95% CI: -0.74, -0.09], p = 0.01); Fasting Blood Sugar: improved (SMD - 1.28[95% CI: -2.42, -0.14], p = 0.03); HOMA-IR: improved (SMD - 0.64[95% CI: -1.22, -0.06], p = 0.03) |
| 13 Nie et al. 2026 | meta-analysis | Oral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trials | Fasting blood glucose: improved (MD, -5.90 mg/dL; 95% CI, -9.65 to -2.15); Glycated hemoglobin A1c: improved (MD, -0.21%; 95% CI, -0.37 to -0.05); Fasting insulin: improved (SMD, -0.55; 95% CI, -0.78 to -0.32) |
| 22 Guan et al. 2020 | meta-analysis | Taurine supplementation (oral intake); 0.5 to 6 g/day; 15 days to 6 months; vs. Control group (placebo) | Total cholesterol: improved (WMD: -10.87 mg/dl; 95%CI, -16.96 to -4.79); Triglycerides: improved (WMD: -13.05 mg/dl; 95%CI, -25.88 to -0.22); Fasting blood glucose: no difference (WMD: 0.06 mg/dl) |
| 25 Moludi et al. 2022 | randomised controlled · 120 participants | Taurine 1 g versus placebo, plus low-calorie diet; 1 g taurine three times per day; eight weeks; vs. placebo plus low-calorie diet | serum insulin and HOMA-IR: improved; fasting blood glucose and glycated hemoglobin: no difference |
| 31 Esmaeili et al. 2021 | randomised controlled · 46 participants | taurine supplement vs. placebo; 3,000 mg/day; 8 weeks; vs. placebo, double-blind randomized | fasting blood sugar: improved (p=0.01); glycated hemoglobin: improved (p=0.04); insulin: improved (p=0.03) |
| 32 Maleki et al. 2020 | randomised controlled · 45 participants | taurine supplementation; 3000 mg daily; 8 weeks; vs. placebo (crystalline microcellulose) | fasting blood sugar (FBS): improved (p = 0.01); insulin: improved (p = 0.01); HOMA-IR: improved (p = 0.003) |
Further studies in this area: 36 69 112 118 120 130 135 136 137 142 146
Taurine and Blood Pressure: Human Studies
Several meta-analyses found lower systolic and diastolic blood pressure with orally ingested taurine, in healthy individuals as well as in people with metabolic, liver or heart diseases 23121322. A randomized controlled trial in type 2 diabetes also found lower systolic blood pressure than with placebo 66. A meta-analysis in people with diabetes mellitus, by contrast, found no difference in blood pressure 8. The strength of evidence is moderate; the studies differ in dose, intake duration and number of participants.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2026 | systematic review · 1,030 participants | Taurine supplementation; optimal 3,000 mg daily; vs. Control in included trials | blood pressure: improved |
| 2 Tzang et al. 2024 | meta-analysis · 1,024 participants | Taurine supplementation (powder/capsule); 0.5 to 6 g per day; 5 to 365 days; vs. Control group | Systolic blood pressure: improved (WMD = -3.999 mmHg, 95% CI = -7.293 to -0.706, p = 0.017); Diastolic blood pressure: improved (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002) |
| 3 Tzang et al. 2024 | meta-analysis · 808 participants | Taurine (form not specified); not reported, meta-regression by total dose; not reported; vs. control group | systolic blood pressure: improved (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017); diastolic blood pressure: improved (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007) |
| 8 Tao et al. 2022 | meta-analysis · 209 participants | Taurine supplement; vs. Control group | Blood pressure: no difference |
| 12 Waldron et al. 2018 | meta-analysis · 103 participants | orally administered isolated taurine; 1 to 6 g/day; 1 day to 12 weeks; vs. control (not further described) | systolic blood pressure: improved (Hedges' g = - 0.70, 95% CI - 0.98 to - 0.41, P < 0.0001); diastolic blood pressure: improved (Hedges' g = - 0.62, 95% CI - 0.91 to - 0.34, P < 0.0001) |
| 13 Nie et al. 2026 | meta-analysis | Oral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trials | Systolic blood pressure: improved (MD, -4.38 mmHg; 95% CI, -7.26 to -1.50); Diastolic blood pressure: improved (MD, -2.54 mmHg; 95% CI, -3.97 to -1.11) |
| 22 Guan et al. 2020 | meta-analysis | Taurine supplementation (oral intake); 0.5 to 6 g/day; 15 days to 6 months; vs. Control group (placebo) | Systolic blood pressure: improved (WMD: -4.67 mm Hg; 95%CI, -9.10 to -0.25); Diastolic blood pressure: improved (WMD: -2.90 mm Hg; 95%CI, -4.29 to -1.52) |
| 66 Li et al. 2025 | randomised controlled | Taurine (oral); 2.4 g/day; 12 weeks; vs. Placebo | Systolic blood pressure: improved |
Further studies in this area: 112 137 145
Taurine, Nerves and Brain: Human Studies
For cognitive performance, a meta-analysis and two systematic reviews found no confirmed advantage of taurine 146. A randomized controlled trial found in traumatic brain injury with taurine in addition to tube feeding a better level of consciousness than without taurine 42. After liver transplantation, delirium occurred less frequently with taurine in a randomized controlled trial than with placebo 68. Combination products with vitamins or caffeine do not allow statements about taurine alone 3340. Populations, doses and intake durations are very different, and for healthy adults null findings predominate.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2026 | systematic review · 1,030 participants | Taurine supplementation; optimal 3,000 mg daily; vs. Control in included trials | neurocognition: no difference |
| 4 Cao et al. 2025 | meta-analysis · 402 participants | taurine, alone or combined with exercise training or therapeutic drugs; vs. exercise training alone, therapeutic drugs alone, placebo | cognitive scores: no difference; Mini-Mental State Examination (taurine plus drugs vs. drugs alone): no difference (WMD = 3.09, 95% CI: 2.29-3.90) |
| 6 Moore et al. 2026 | systematic review · 244 participants | oral taurine, acute single dose; sometimes combined with caffeine; typically 1-3 g, up to ~50 mg/kg; acute single dose; vs. placebo or control; sometimes taurine plus caffeine | cognitive performance: no difference; mood and well-being: unclear |
| 9 Verner et al. 2007 | systematic review · 189 participants | Taurine supplementation, mostly enteral with formula milk, one trial parenteral; Neonatal period until 3–4 months chronological age; vs. Taurine supplementation versus no supplementation | Long-term growth or neurological outcomes: unclear (no data) |
| 11 Pedregosa et al. 2026 | review · 130 participants | taurine (single agent, oral intake); vs. no taurine control arm in this review | association between dietary taurine intake and depression: no difference; antidepressant- and anxiolytic-like effects in animal models: improved |
| 41 Köse et al. 2026 | randomised controlled · 32 participants | Taurine 10 mg/kg oral, alone and with caffeine 2 mg/kg; Taurine 10 mg/kg; caffeine 2 mg/kg; acute single dose; vs. placebo and caffeine alone, double-blind randomized crossover | cognitive performance: no difference (p > 0.05) |
| 42 Vahdat et al. 2021 | randomised controlled · 32 participants | taurine added to standard enteral meal vs. standard enteral meal alone; 30 mg/kg/day taurine; 14 days; vs. taurine plus standard enteral meal vs. standard enteral meal alone | Glasgow coma scale: improved (p = 0.03) |
| 58 Liu et al. 2025 | randomised controlled · 16 participants | Taurine 50 mg/kg, caffeine 5 mg/kg, taurine+caffeine, placebo (maltodextrin 5 mg/kg); Taurine 50 mg/kg; caffeine 5 mg/kg; Single dose before exhaustion and sprint tests in hypoxia; vs. Placebo (maltodextrin 5 mg/kg) | Stroop Test response time: no difference |
Further studies in this area: 68 72 86 94 96 97 100 103 104 107 108 110 112 113 116 120 121 125 128 131 139 142
Taurine, Aging and Longevity: Human Studies
A randomized controlled trial with older women found higher levels of the antioxidant enzyme SOD with taurine than with placebo 47. The oxidative marker malondialdehyde rose only in the placebo group 47. The strength of evidence is low, since only one controlled trial with a small number of participants is available. One review sees a benefit of taurine supplementation for healthy aging 118, another for protection against mitochondrial defects 139. A further review suggests that a mixture of taurine and glutamine together with training could counteract muscle loss in old age 121.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 47 Abud et al. 2022 | randomised controlled · 24 participants | Taurine or placebo (1.5 g starch); 1.5 g daily; 16 weeks; vs. Placebo group (1.5 g starch) | superoxide dismutase (SOD): improved (SOD levels also were higher than in the GC group); glutathione reductase: no difference (decreased regardless of the intervention); malondialdehyde: improved (increased only in the GC participants) |
| 81 Marcangeli et al. 2025 | cross-sectional study · 137 participants | no preparation; measurement of circulating taurine; vs. no comparison; cross-sectional analysis by age and activity | association of taurine with age: no difference |
| 99 Frascatani et al. 2026 | cohort study | Taurine (serum levels, no administration); median 45 months follow-up; vs. IBD patients vs. healthy controls | Age-related taurine decline in healthy controls: no difference |
| 118 Beine et al. 2026 | review | Taurine supplementation; 1-6 g per day; vs. no comparator arm reported | healthy aging: improved |
| 121 Chen et al. 2026 | review | taurine and glutamine supplementation, partly with exercise regimens | muscle mass, strength and neuromuscular efficacy: unclear |
| 139 Jong et al. 2021 | review | Taurine supplementation | Protection against mitochondrial defects: improved |
Taurine, Eye and Retina: Human Studies
A review suggests that taurine as a dietary supplement could alleviate visual fatigue; controlled studies with taurine alone on the eye are still pending 15. A randomized controlled trial with 43 healthy participants found with a combination product of taurine with vitamin C, vitamin E, zinc, lutein/zeaxanthin, selenium, aronia extract and omega-3 fatty acids more favorable values for retinal artery diameter, erythrocyte velocity in retinal vessels and retinal blood flow 35; since no arm here received taurine alone, the effect cannot be attributed to the taurine. The strength of evidence is low, because no controlled study has tested taurine alone on the eye. It remains open whether taurine alone acts on the eye.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 15 Duan et al. 2023 | systematic review | Taurine (endogenous sources, diet, supplements) | Visual fatigue: improved |
| 87 Hiller et al. 2025 | case-control study · 23 participants | No taurine administration; vitreous metabolite measurement; vs. DR groups versus controls | vitreous taurine in NPDR: worsened (p < 0.01) |
| 95 Horvath et al. 2016 | case series · 2 participants | L-taurine supplementation, oral; vs. Before-after under vigabatrin therapy | Electroretinogram changes: improved |
| 101 Ullah et al. 2026 | case series | No taurine administration; SLC6A6 variants and plasma taurine assessed; vs. Heterozygous carriers and healthy controls | Taurine transport in HEK-293 cells and patient-derived fibroblasts: worsened (complete loss of taurine transport) |
| 133 García-Ayuso et al. 2024 | review | Taurine (review, no primary study) | retinal taurine deficiency: worsened; taurine administration as neuroprotection: unclear |
| 138 Castelli et al. 2021 | review | Taurine (supplementation) | Slowing of progression of degenerative retinal diseases: improved; Improvement of retinal reduced glutathione, malondialdehyde, superoxide dismutase, and catalase: improved; Antiapoptotic effects: improved |
Taurine: Further Outcomes in Studies
Inflammatory markers decreased more strongly than with placebo in two randomized controlled trials 2761, markers of oxidative stress in two others 3846. Total and LDL cholesterol decreased more strongly than in the comparison group in two randomized controlled trials 3269, liver values in two others 2438. For clinical endpoints, several controlled studies found advantages, for example for muscle cramps in chronic liver disease 30, in ventilated children 27 and after liver transplantation 24. These are contrasted by results without difference, for example for anthropometry and body weight 485969 as well as for several inflammatory and oxidation markers 445176. Combination products with N-acetylcysteine 2628, with caffeine 54 or with numerous other substances 67 do not allow conclusions about taurine alone.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2026 | systematic review · 1,030 participants | Taurine supplementation; optimal 3,000 mg daily; vs. Control in included trials | total cholesterol, triglycerides, LDL: improved; inflammatory markers CRP, TNF-α, IL-6: improved; oxidative stress (malondialdehyde): improved |
| 7 Cao et al. 2018 | meta-analysis · 216 participants | Taurine supplementation (form not reported); vs. control without taurine | length gain: worsened (WMD:-0.18; P < 0.001); plasma glycine: worsened (WMD:-106.71; P = 0.033); plasma alanine: worsened (WMD:-229.30; P = 0.002) |
| 8 Tao et al. 2022 | meta-analysis · 209 participants | Taurine supplement; vs. Control group | Serum lipids: no difference; Body composition: no difference |
| 9 Verner et al. 2007 | systematic review · 189 participants | Taurine supplementation, mostly enteral with formula milk, one trial parenteral; Neonatal period until 3–4 months chronological age; vs. Taurine supplementation versus no supplementation | Intestinal fat absorption: improved (weighted mean difference 4.0 (95% confidence interval 1.4, 6.6) percent of intake); Rate of weight gain: no difference (weighted mean difference -0.25 (95% confidence interval -1.16, 0.66) grams/kilogram/day); Change in length: no difference (weighted mean difference 0.37 (95% confidence interval -0.23, 0.98) millimetres/week) |
| 13 Nie et al. 2026 | meta-analysis | Oral taurine supplementation; 1.5-3.0 g daily most effective; ≥8 weeks for glucose/lipid metabolism, <8 weeks for blood pressure/inflammation; vs. Control group of randomized trials | Aspartate aminotransferase: improved (MD, -9.65 U/L; 95% CI, -17.39 to -1.90); Alanine aminotransferase: improved (MD, -8.26 U/L; 95% CI, -14.81 to -1.70); C-reactive protein: improved (SMD, -1.26; 95% CI, -2.01 to -0.52) |
| 14 Roberts et al. 2025 | systematic review | Taurine supplementation; vs. Placebo | Cramp frequency, severity, and duration: improved |
| 17 Faghfouri et al. 2022 | meta-analysis | Taurine supplementation; various doses (dose-response analysis); various durations, 56 days more beneficial; vs. Control group | Malondialdehyde (MDA): improved (SMD = -1.17 µmol/l; 95% CI: -2.08, - 0.26; P = 0.012); C-reactive protein (CRP): improved (SMD = -1.95 mg/l; 95% CI: -3.20, - 0.71; P = 0.002); Tumor necrosis factor-alpha (TNF-α): no difference (SMD = -0.18 pg/ml; 95% CI: -0.56, 0.21; P = 0.368) |
| 19 Mirjalili et al. 2022 | systematic review | Taurine among 22 other compounds; vs. Control without nephroprotective agent, not reported | Nephroprotective effect during colistin exposure: improved |
Further studies in this area: 20 22 23 24 25 26 27 28 29 30 31 32 34 36 37 38 39 42 44 46 48 49 50 51 53 54 56 57 59 61 62 63 64 67 69 71 73 74 76 78 80 82 83 84 85 88 89 90 91 92 93 94 96 98 99 101 102 105 106 108 109 110 111 114 115 117 118 120 121 123 126 127 132 134 135 140 141 142 143 144
4. How Is Taurine Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used oral taurine as a single substance in powder or capsule form, sometimes as an acute single dose, sometimes over several weeks. Individual investigations used combination products with caffeine, vitamins or other substances. The doses and intake durations are shown in the table.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Oral L-taurine plus standard care | 1000 mg per day | 12 weeks | 23 |
| Oral taurine supplementation vs. placebo | 2 g/day | Transplant day to day 30 | 24 |
| Taurine 1 g versus placebo, plus low-calorie diet | 1 g taurine three times per day | eight weeks | 25 |
| Nefrosave®: NAC 150 mg + taurine 500 mg | twice daily | 180 days | 26 |
| taurine or placebo capsules plus standard care | 30 mg/kg/day in divided doses | from PICU admission until PICU discharge | 27 |
| NT arm: 500 mg taurine + 150 mg NAC; NP arm: 300 mg NAC + 50 mg pyridoxamine | twice daily, 500 mg taurine + 150 mg NAC per intake | 6 months, monthly assessment | 28 |
| Taurine capsule (1000 mg) vs. placebo (crystalline microcellulose) | 1000 mg taurine three times daily | 8 weeks | 29 |
| Oral taurine supplementation | 2 g taurine per day | 4 weeks per arm, crossover | 30 |
| taurine supplement vs. placebo | 3,000 mg/day | 8 weeks | 31 |
| taurine supplementation | 3000 mg daily | 8 weeks | 32 |
| blend of taurine, vitamins B6, B9 and B12 | — | four-week supplementation | 33 |
| Oral taurine supplementation | 3 g/day | 12 weeks | 34 |
| Dietary supplement containing taurine and other ingredients | — | 14 days daily | 35 |
| oral taurine supplementation | — | 8 weeks | 36 |
| oral taurine vs. placebo, double-blind randomized | 2 g per day in two doses, 6 h after chemotherapy | 6 months | 37 |
5. Is Taurine Safe? Side Effects in Studies
The included studies predominantly report no or only mild side effects, such as gastrointestinal complaints 232350. In a randomized controlled trial, mild adverse events occurred in some of the participants 23. In mice with a predisposition to lupus, supplemental taurine increased autoantibodies and kidney inflammation; whether this applies to people with lupus is open 111.
| Study | Reported side effects |
|---|---|
| 2 Tzang et al. 2024 | No significant adverse effects versus control |
| 3 Tzang et al. 2024 | no significant adverse effects versus controls |
| 11 Pedregosa et al. 2026 | no serious adverse events in included human studies |
| 12 Waldron et al. 2018 | no adverse events reported |
| 14 Roberts et al. 2025 | Only pregabalin had significant side effects; no data for taurine |
| 15 Duan et al. 2023 | Safety of consumption is reviewed |
| 18 McGurk et al. 2022 | no significant safety concerns reported |
| 23 Sasidharan et al. 2026 | 11.8% with taurine, all mild |
| 26 Bhalla et al. 2026 | mild adverse events in five participants in the test arm |
| 30 Vidot et al. 2018 | No adverse side effects associated with taurine supplementation |
| 37 Islambulchilar et al. 2015 | adverse effects assessed by questionnaire; none specific reported |
| 39 Islambulchilar et al. 2015 | side effects assessed by questionnaire, no numbers reported |
6. What Remains Open: Limits of the Evidence
- Most studies are small and short; women, older people and long-term endpoints are underrepresented.
- For taurine eye drops, infusion solutions and infant formula, hardly any controlled findings are available.
- Combination preparations with caffeine or other substances do not allow conclusions about taurine alone.
- The optimal dose and intake duration are open for most endpoints.
- For clinical endpoints such as heart failure or cognitive performance, the results are inconsistent.
7. Bottom Line: What Is Established About Taurine
Taurine is a sulfur-containing compound that the body produces itself and takes in through animal foods. Human studies show benefits for blood pressure, vascular function and blood sugar for oral taurine as a single substance; for physical performance they are small and uncertain. The findings come predominantly from small, short studies in young, trained men or in people with metabolic disorders. For healthy adults, null findings predominate in cognitive tests. For taurine eye drops, infusion solutions and infant formula, the data are thin. Combination preparations with caffeine or other substances do not allow any statement about taurine alone.
Frequently Asked Questions
How well has Taurine been studied in humans?
We evaluated 153 human studies on Taurine, including 51 randomised controlled trials and 21 meta-analyses or systematic reviews; the controlled studies include 1,885 participants in total. As of 8 October 2026.
Does Taurine help with physical performance? What the studies show
Does Taurine help with heart and circulation? What the studies show
Does Taurine help with blood sugar and metabolism? What the studies show
Does Taurine help with blood pressure? What the studies show
Does Taurine help with nerves and brain? What the studies show
Does Taurine help with aging and longevity? What the studies show
Does taurine improve athletic performance?
How does taurine affect blood pressure?
Several meta-analyses found lower systolic and diastolic blood pressure with orally ingested taurine, in healthy people as well as in people with metabolic, liver or heart disease 23121322. A randomized controlled trial in type 2 diabetes also found lower systolic blood pressure than with placebo 66. A meta-analysis in people with diabetes mellitus, by contrast, found no difference in blood pressure 8. The strength of evidence is moderate.
Are there studies on taurine eye drops?
A review suggests that taurine as a dietary supplement could alleviate visual fatigue; controlled studies with taurine alone on the eye are still pending 15. A randomized controlled trial with a combination product of taurine and other substances found more favorable retinal values, but does not allow conclusions about taurine alone 35. It remains open whether taurine alone acts on the eye.
What side effects are known?
Can taurine improve blood sugar?
Several meta-analyses found lower fasting blood sugar with oral taurine, and in people with diabetes also lower long-term blood sugar and less insulin resistance 12813. In two randomized controlled trials in type 2 diabetes, fasting blood sugar, insulin and insulin resistance decreased more than with placebo 3132. A third study found a benefit only for insulin and insulin resistance, not for blood sugar 25. The findings come predominantly from powder or capsule administration in patients with metabolic disorders.
Sources
- 1Wang K, Ma CH, Khoramjoo M, Kung JY, Oudit GY · 2026
- 2Tzang CC, Chi LY, Lin LH, Lin TY, Chang KV, Wu WT et al. · 2024
- 3Tzang CC, Lin WC, Lin LH, Lin TY, Chang KV, Wu WT et al. · 2024
- 4Cao Q, Nie Z, Liu Y, Xu J, Chen L, Han S · 2025
- 5Deng H, Song T, Yin M, Xu K, Zhong Y, Liu P et al. · 2025
- 6Moore JA, Cousins AL, Taylor RMJ, Griffiths AR, Young HA · 2026
- 7Cao SL, Jiang H, Niu SP, Wang XH, Du S · 2018
- 8Tao X, Zhang Z, Yang Z, Rao B · 2022
- 9Verner A, Craig S, McGuire W · 2007
- 10The effect of taurine supplementation on markers of muscle damage and muscle pain in an athletic population: A systematic review and meta-analysis of randomized controlled trials assessed using the grading of recommendations, assessment, development, and evaluation approachDehghani E, Naeini F, Bidar SS, Beba M, Mortezapour E, Nourian R et al. · 2025
- 11Pedregosa BIC, Navarro JC, Baroque GAB, Sta Maria MIN, De Leon MAJ, Trivilegio MJH et al. · 2026
- 12Waldron M, Patterson SD, Tallent J, Jeffries O · 2018
- 13Nie Z, Liu Y, Zhang M, Wu C, Cao Q, Xu J et al. · 2026
- 14Roberts AT, Makar J, Abdelmalak J, Sinclair M, Testro A, Majumdar A · 2025
- 15Duan H, Song W, Guo J, Yan W · 2023
- 16Buzdağlı Y, Eyipınar CD, Tekin A, Şıktar E, Zydecka KS · 2022
- 17Faghfouri AH, Seyyed Shoura SM, Fathollahi P, Shadbad MA, Papi S, Ostadrahimi A et al. · 2022
- 18
- 19Mirjalili M, Mirzaei E, Vazin A · 2022
- 20Almeida CC, Mendonça Pereira BF, Leandro KC, Costa MP, Spisso BF, Conte-Junior CA · 2021
- 21Kurtz JA, VanDusseldorp TA, Doyle JA, Otis JS · 2021
- 22
- 23Sasidharan S, Philips CA, Philips CA, Tharakan A, Ahamed R, Oommen TT et al. · 2026
- 24Mottaghi S, Vazin A, Nikoupour H, Firoozifar SM, Haem E, Heidari R et al. · 2026
- 25Moludi J, Qaisar SA, Kadhim MM, Ahmadi Y, Davari M · 2022
- 26Bhalla AK, Kumar S, Verma H, Sheth G, Kumar B, Mondal R et al. · 2026
- 27Shirzad-Yazdi N, Shorafa E, Abootalebi SN, Heidari R, Hojabri K, Doostfatemeh M et al. · 2024
- 28Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney DiseaseSengupta P, Biswas S, Roy T · 2022
- 29Maleki V, Mahdavi R, Hajizadeh-Sharafabad F, Alizadeh M · 2020
- 30Vidot H, Cvejic E, Carey S, Strasser SI, McCaughan GW, Allman-Farinelli M et al. · 2018
- 31
- 32Maleki V, Alizadeh M, Esmaeili F, Mahdavi R · 2020
- 33Anlacan VM, Jamora RDG, Krattinger LF, De Longis E, Hartweg M, Steinmann M et al. · 2026
- 34Saedmocheshi S, Dhahbi W, Saeidi A, Rahmani A · 2026
- 35Told R, Schmidl D, Palkovits S, Boltz A, Gouya G, Wolzt M et al. · 2014
- 36Samadpour Masouleh S, Bagheri R, Ashtary-Larky D, Cheraghloo N, Wong A, Yousefi Bilesvar O et al. · 2021
- 37Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M · 2015
- 38Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M · 2015
- 39Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M · 2015
- 40O'Shea OK, Lawley N, Azzopardi A, Gutkowski A, Niedziela MM, Horn R et al. · 2024
- 41
- 42Vahdat M, Hosseini SA, Soltani F, Cheraghian B, Namjoonia M · 2021
- 43Buzdağlı Y, Eyipınar CD, Öget F, Şıktar E, Forbes SC, Tekin A · 2023
- 44Lak S, Ostadrahimi A, Nagili B, Asghari-Jafarabadi M, Beigzali S, Salehi F et al. · 2015
- 45Ra SG, Choi Y, Akazawa N, Kawanaka K, Ohmori H, Maeda S · 2019
- 46Ra SG, Choi Y, Akazawa N, Ohmori H, Maeda S · 2016
- 47Abud GF, De Carvalho FG, Batitucci G, Travieso SG, Bueno Junior CR, Barbosa Junior F et al. · 2022
- 48De Carvalho FG, Brandao CFC, Batitucci G, Souza AO, Ferrari GD, Alberici LC et al. · 2021
- 49Batitucci G, Brandao CFC, De Carvalho FG, Marchini JS, Pfrimer K, Ferrioli E et al. · 2019
- 50Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B et al. · 2018
- 51da Silva LA, Tromm CB, Bom KF, Mariano I, Pozzi B, da Rosa GL et al. · 2014
- 52Bi̇lgi̇n S, Bi̇lgi̇n S, Buzdağli Y, Ozan M, Yilmaz U, Çi̇ydem Ç et al. · 2026
- 53
- 54Karayigit R, Naderi A, Saunders B, Forbes SC, Coso JD, Berjisian E et al. · 2021
- 55Milioni F, Malta Ede S, Rocha LG, Mesquita CA, de Freitas EC, Zagatto AM · 2016
- 56
- 57Li X, Huo L, Wang L, Zhang W · 2025
- 58
- 59De Carvalho FG, Brandao CFC, Muñoz VR, Batitucci G, Tavares MEA, Teixeira GR et al. · 2021
- 60Ahmadian M, Dabidi Roshan V, Ashourpore E · 2017
- 61Rosa FT, Freitas EC, Deminice R, Jordão AA, Marchini JS · 2014
- 62Peel JS, McNarry MA, Heffernan SM, Nevola VR, Kilduff LP, Coates K et al. · 2024
- 63
- 64McLeay Y, Stannard S, Barnes M · 2017
- 65Moloney MA, Casey RG, O'Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ · 2010
- 66Li Y, Wang Q, Liu Y, Li Q, Xia W, Lin S et al. · 2025
- 67Cai T, Palumbo F, Miacola C, Ceruti C, Rizzo M, Liguori G et al. · 2024
- 68Mottaghi S, Nikoupour H, Firoozifar M, Jalali SS, Jamshidzadeh A, Vazin A et al. · 2022
- 69Haidari F, Asadi M, Mohammadi-Asl J, Ahmadi-Angali K · 2020
- 70Ahmadian M, Roshan VD, Aslani E, Stannard SR · 2017
- 71Van Stijn MF, Bruins AA, Vermeulen MA, Witlox J, Teerlink T, Schoorl MG et al. · 2015
- 72Chupel MU, Minuzzi LG, Furtado G, Santos ML, Hogervorst E, Filaire E et al. · 2018
- 73Carvalho MB, Brandao CFC, Fassini PG, Bianco TM, Batitucci G, Galan BSM et al. · 2020
- 74Simmonds R, Cole J, Tallent J, Jeffries O, Theis N, Waldron M · 2022
- 75Aggett J, Page J, Peel J, John K, Matta G, Tallent J et al. · 2025
- 76Wang Y, Xu T, Zhao H, Gu C, Li Z · 2022
- 77Paulucio D, Costa BM, Santos CGM, Nogueira F, Koch A, Machado M et al. · 2017
- 78Ra SG, Miyazaki T, Ishikura K, Nagayama H, Komine S, Nakata Y et al. · 2013
- 79van Vugt M, Finan C, Chopade S, Providencia R, Bezzina CR, Asselbergs FW et al. · 2024
- 80Post A, Said MY, Gomes-Neto AW, van der Krogt J, de Blaauw P, Berger SP et al. · 2019
- 81Marcangeli V, Cefis M, Hammad R, Granet J, Leduc-Gaudet JP, Gaudreau P et al. · 2025
- 82Wu H, Zhang X, Yang J, Feng T, Chen Y, Feng R et al. · 2022
- 83Dogan S, Aydin T, Koroglu N, Yilmazer Y, Albayrak N, Cetin F et al. · 2024
- 84Porto G, Pitino A, Gori M, Pitea M, Alvaro ME, Tripepi GL et al. · 2025
- 85Kotb RR, Afifi AM, El-Houseini ME, Ezz-Elarab M, Basalious EB, Omran MM et al. · 2023
- 86Kofler M, Schiefecker A, Ferger B, Beer R, Sohm F, Broessner G et al. · 2015
- 87Hiller JK, Sand ES, Rootwelt H, Vassli AØ, Lumi X, Moe MC et al. · 2025
- 88Abd El Rahiem R, Ibrahim SA, Effat H, El-Houseini ME, Osman RA, Abdelraouf A et al. · 2024
- 89Verzì AE, Nasca MR, Dall'Oglio F, Cosentino C, Micali G · 2021
- 90Hatab HM, Abdel Hamid FF, Soliman AF, Al-Shafie TA, Ismail YM, El-Houseini ME · 2019
- 91Makhova AA, Shikh EV, Bulko TV, Sizova ZM, Shumyantseva VV · 2019
- 92Li H, Wang Z, He S, Zhao X, Wu Q, Sun Y et al. · 2025
- 93Jang ES, Hwang SH, Kim JW, Jeong SH · 2021
- 94Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H et al. · 2019
- 95Horvath GA, Hukin J, Stockler-Ipsiroglu SG, Aroichane M · 2016
- 96Rikimaru M, Ohsawa Y, Wolf AM, Nishimaki K, Ichimiya H, Kamimura N et al. · 2012
- 97Yoshida R, Mitsuno R, Nakayama T, Azegami T, Hashiguchi A, Torimitsu T et al. · 2025
- 98Imasawa T, Kitamura H, Kawaguchi T, Yatsuka Y, Okazaki Y, Murayama K · 2023
- 99Frascatani R, Mattogno A, Salvatori S, Iannucci A, Marafini I, Monteleone G · 2026
- 100di Vito R, Hassan A, Nuzzo T, Caretto A, Panicucci C, Bruno C et al. · 2026
- 101Ullah M, Rehman AU, Shetty M, Allen MD, Ullah E, Signorini SG et al. · 2026
- 102Kyriakopoulos AM, McCullough PA, Seneff S · 2026
- 103Zhang N, Borné Y, Hagberg E, Palmqvist S, Glans I, Ottosson F et al. · 2025
- 104Wang T, Huang X, Zhang X, Li N, Lu K, Zeng Y · 2025
- 105Sayedyousef H, Yilmaz O, Ozturk C, Demir B, Toygar HU, Balci N · 2025
- 106Khoramjoo M, Wang K, Srinivasan K, Gheblawi M, Mandal R, Rousseau S et al. · 2024
- 107
- 108Sunada Y · 2024
- 109Mahmoodpoor A, Farjami A, Farzan N, Hamishehkar H, Asgharian P, Sanaie S et al. · 2023
- 110Li H, Xu H, Li Y, Jiang Y, Hu Y, Liu T et al. · 2020
- 111Li J, Ding H, Meng Y, Li G, Fu Q, Guo Q et al. · 2020
- 112Sak D, Erdenen F, Müderrisoglu C, Altunoglu E, Sozer V, Gungel H et al. · 2019
- 113Spelbrink EM, Mabud TS, Reimer R, Porter BE · 2016
- 114Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ · 2012
- 115Chiarla C, Giovannini I, Siegel JH, Boldrini G, Castagneto M · 2000
- 116
- 117Zheng Y, Liu H, Liu X, He W · 2026
- 118Beine BJ, Castellano M, Fiamoncini J, Hiller K · 2026
- 119Mirzohreh ST, Ghaffari S, Mesri Alamdari N, Banisefid E, Ghaffari M, Shabestari AN et al. · 2026
- 120
- 121
- 122Huang X, Zhu J, Zang P, Chen J, Chen P, Xu N et al. · 2026
- 123Naddafha S, Stout JR, Evans C · 2026
- 124Dai X, Liu S, Zou D, Zou S, Shao X, Jiang Y et al. · 2026
- 125Zanza C, Longhitano Y, Planinsic R, Voza A, Tesauro M, Caputo G et al. · 2026
- 126Bjørklund G, Izmailovich M, Nurpeissov T, Glushkova N, Semenova Y · 2026
- 127Jiang Y, Tao Q, Qiao X, Yang Y, Peng C, Han M et al. · 2025
- 128Rana A, Katiyar A, Arun A, Berrios JN, Kumar G · 2025
- 129Nieto ÁVA, Diaz AH, Hernández M · 2025
- 130Fogagnolo C, Ortiz GU, Travieso SG, Rossini-Venturini AC, Abud GF, Silva BM et al. · 2025
- 131Beretta V, Scarpa E, Carloni S, Petrolini C, Dell'Orto V, Ravenda S et al. · 2025
- 132Chen SH, Chen L · 2025
- 133García-Ayuso D, Di Pierdomenico J, Martínez-Vacas A, Vidal-Sanz M, Picaud S, Villegas-Pérez MP · 2024
- 134
- 135Ahmed K, Choi HN, Yim JE · 2023
- 136Li C, Gao L, Lv C, Li Z, Fan S, Liu X et al. · 2023
- 137Bae M, Ahmed K, Yim JE · 2022
- 138Castelli V, Paladini A, d'Angelo M, Allegretti M, Mantelli F, Brandolini L et al. · 2021
- 139Jong CJ, Sandal P, Schaffer SW · 2021
- 140
- 141Hussain T, Tan B, Murtaza G, Metwally E, Yang H, Kalhoro MS et al. · 2020
- 142Schaffer S, Kim HW · 2018
- 143De Luca A, Pierno S, Camerino DC · 2015
- 144Spriet LL, Whitfield J · 2015
- 145Role of taurine in the vasculature: an overview of experimental and human studiesAbebe W, Mozaffari MS · 2011
- 146Taurine and glucose metabolism: a reviewDe la Puerta C, Arrieta FJ, Balsa JA, Botella-Carretero JI, Zamarrón I, Vázquez C · 2010
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.